Carl Gibson, MD
Endocrinology, Diabetes & Metabolism · Newport News, VANPI 1003888264
Payments from drug & device makers
Across 50 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$172
- Lilly USA, LLC$134
- Boehringer Ingelheim$82
- Dexcom, Inc.$74
- Sanofi-aventis U.S. LLC$57
- Novo Nordisk$57
- plus $489 from 16 others
What the payments were for
- Food & beverage$1,065100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 4 | $172 |
| Lilly USA, LLC | 7 | $134 |
| Boehringer Ingelheim | 4 | $82 |
| Dexcom, Inc. | 4 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Novo Nordisk | 3 | $57 |
| Merck | 4 | $55 |
| BETA Bionics, Inc. | 2 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Corcept Therapeutics | 2 | $46 |
| Amgen | 2 | $39 |
| AstraZeneca | 2 | $34 |
| Ascensia Diabetes Care US Inc. | 1 | $28 |
| Radius Health, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Antares Pharma, Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| Sanofi US Services Inc. | 1 | $24 |
| Mannkind Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| AbbVie | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$111
How this compares
$1,065 in reported general payments places this provider in the 40th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 373 | $621,084 |
| JardianceEmpagliflozin | 273 | $285,378 |
| TrulicityDulaglutide | 168 | $236,293 |
| MounjaroTirzepatide | 156 | $190,751 |
| RybelsusSemaglutide | 112 | $159,055 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 112 | $113,671 |
| JanuviaSitagliptin Phosphate | 66 | $72,153 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $71,589 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 382 | $65,976 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $58,015 |
| JanumetSitagliptin Phos/Metformin Hcl | 70 | $55,206 |
| TradjentaLinagliptin | 59 | $52,985 |
| Teriparatide | 13 | $44,144 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 48 | $42,651 |
| Humalog Kwikpen U-100Insulin Lispro | 101 | $38,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $57 | $800,613517 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $134 | $448,806383 claims |
| Boehringer IngelheimJardiance, Tradjenta | $82 | $338,363332 claims |
| MerckJanuvia, Janumet, Janumet Xr | $55 | $170,010184 claims |
| AstraZenecaFarxiga | $34 | $35,07943 claims |
| AbbVieSynthroid | $14 | $11,397150 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $5,020509 claims |
| Sanofi-aventis U.S. LLCLantus | $57 | $4,13639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Newport News
- Dwight MatthiasNewport News$29K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.